Clinical Trial Update: Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of SLV339 for pancreatic exocrine insufficiency due to chronic pancreatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Drugs mentioned

• SLV339

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis | Phase 2 | Status: TERMINATED